Intellia Therapeutics Stock
Intellia Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John Leonard
- Employees
- 377
- Market cap
- $1.6 B
- IPO
- 06/05/2016
Intellia Therapeutics, Inc. (NTLA) operates in the healthcare / biotechnology sector and specializes in the development of therapies through genome editing. Headquartered in Cambridge, Massachusetts, the company focuses on applications of the CRISPR/Cas9 system. Its medical programs include in vivo approaches such as…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Intellia Therapeutics stock: price history
1D
+0.7%
1W
-12.6%
1M
-0.6%
6M
-23.6%
YTD
+27.0%
1Y
-54.2%
2Y
-44.5%
5Y
-91.2%
10Y
-5.0%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~22% stronger price swings than usual
Intellia Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Intellia Therapeutics focuses on developing therapies using CRISPR/Cas9 technology for genome editing. The portfolio comprises in vivo programs such as NTLA-2001 as well as ex vivo candidates for the treatment of leukemia and other diseases. Through collaborations with partners like Novartis and Regeneron Pharmaceuticals, the company expands its expertise in the field of cell therapies. The current focus lies on the clinical development of various approaches in the areas of oncology and autoimmune diseases.
- Revenue model
- Licensing
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Regeneron Pharmaceuticals, Inc.DescriptionAsk the agents about Intellia Therapeutics
Analyst assessment of Intellia Therapeutics
PRICE TARGET LOW
US$8.00
CONSENSUS
US$21.64
MEDIAN
US$17.00
PRICE TARGET HIGH
US$49.00
0
STRONG BUY
29
BUY
7
HOLD
3
SELL
0
STRONG SELL
39
TOTAL · Buy
As of: 09/09/2026
Intellia Therapeutics stock metrics
P/E
-3.4
P/B
2.09
EV/EBITDA
-4.02
RETURN ON EQUITY
-14.7%
NET MARGIN
-1,392.3%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.6%
FLOAT SHARES
133,941,514
AVG. DAILY VOLUME (30D)
5,441,585
Insider transactions (SEC)
Dube Michael P
LEONARD JOHN M
LEONARD JOHN M
Dulac Edward J III
Dube Michael P
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.7%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Intellia Therapeutics stock
What does Intellia Therapeutics do?
Intellia Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John Leonard, the company employs around 377 people.
The IPO was on 06/05/2016; the stock trades on NASDAQ under the ticker NTLA.
What do analysts say about Intellia Therapeutics stock?
39 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$21.64, ranging from US$8.00 to US$49.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Intellia Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 22% stronger than usual.
Does Intellia Therapeutics pay a dividend?
No, Intellia Therapeutics currently does not pay a dividend.
Which stocks are comparable to Intellia Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Intellia Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Intellia Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.